Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients

This is an interventional treatment trial for Rectal Neoplasms focused on measuring rectal neoplasms, aged, radiotherapy, drug therapy, dose-escalation, capecitabine Read More

Inclusion Criteria:

• rectal adenocarcinoma, pathological stage II/III(T3-4 or N+, UICC 2002), radical surgery received.
• interval between surgery and enrollment no less than two week and no more than 3 months.
• KPS status no less than 70; life expectancy no less than 6 months.
• without life-threatening complications, such as severe hypertension, coronary heart disease, cerebral vascular disease, uncontrolled diabetes, etc.
• without severe drug allergy history.
• hemoglobin >= 100g/L, white blood cell >= 3.5*10E9/L, neutrophil >= 1.5*10E9/L, platelet >= 100*10E9/L.
• Creatin <= 1.5* ULN(upper limit of normal), Total bilirubin <= 2.5 ULN, AST and AST <= 2.5* ULN, AKP <= 2.5*ULN
• do not receive chemotherapy before six months from enrollment.
• no previously pelvic irradiation history
• informed consent signed

Exclusion Criteria:

• other cancer history, except curable non-melanoma skin cancer or cervix in-situ carcinoma
• allergy history to thymidine phosphorylase
• previous pelvic irradiation history
• receiving adjuvant chemotherapy in six months before enrollment
• active infection existed
• severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes ( Plasma glucose concentrations in any time of a day≥11.1mmol/L）, severe cardiac arrhythmia， etc.
• life expectancy less than 6 months
• estimated cannot finish treatment
• attend other clinical trials in four weeks before enrollment
• receive other anti-cancer treatment currently
• other conditions which regarded illegal by censors with full reasons. for example, some conditions may conflict from the protocol.